Hot dog! Has anyone checked out the chart?? For the first

New Post Public Reply Private Reply Replies (0) Message Board
joey68
Hot dog! Has anyone checked out the chart??
For the first time since June 2015, the 50MA and 100MA are only .0001 away from crossing!

I use 3 MA lines:
50MA
100MA
200MA

And get this..
The last time the 50MA was moving up towards the 100MA (not down and away) was all the way back in MARCH 2015! This chart is changing momentum as we speak even during these red days!

Very nice.

SpectraSCIENCE Inc. (SCIE) Stock Research Links

SCIE Board Company Profile Buy Rating Time & Sales News Filings Financials
View My Board Here:
http://investorshangout.com/Joeys-Investment-Board-91611/


Invite Only

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.

Disclaimer:
As used herein, the terms "You" and "Your" shall mean you, individually, the reader, and each other party on whose behalf you may use the contained information at any time.
All references to "My", "I", and “The writer of the above post” shall refer to the creator of the username Joey68.

Do NOT invest unless you are prepared to sustain a total loss of the money you have invested plus any commission or other transaction charges.

There is a very high degree of risk involved in trading and investing. Past results are not indicative of future returns. I assume no responsibility for your trading and investment results. You should NOT rely on the information in the above post to make any decision or take any action.

ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are OPINION and NOT fact and are for entertainment purposes only. Do your own research and make your own decisions based on your own conclusions.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are NOT advice, and are NOT designed to substitute the expertise and judgment of a professional. It is your responsibility to seek investment advice during all stages of your investments. It is your responsibility to evaluate the accuracy, completeness and usefulness of the information in the above post.
I am NOT a professional.
I do NOT work for you.
My posts are NOT investment advice. I am not paid to post.
There is no correlation between the number of posts I write per day and your assumed success of a company.
It is NOT my responsibility to inform you of my own personal investment decisions.
It is NOT my responsibility to inform you when it is time for you to buy, hold, and/or sell a position.
I have no control over, and am not responsible for the actions of others who copy, store, edit, change, prepare any derivative work of or alter in any way any of the content provided in my posts.
Errors and Omissions expected. The writer of the above post accepts no liability or responsibility for any errors or omissions contained in the above post or contained within this Disclaimer.
The writer of the above post shall NOT accept any liability for the accuracy or completeness of the information contained in the above post, for any reliance placed by any person on the information contained in the above post, or for any damage or loss, however caused, in connection with the use or reliance on any information contained in the above post.
The above post may contain links to websites owned and operated by third parties. These links are provided for informational purposes only and are NOT endorsed by the writer of the above post. The writer of the above post has no control over the contents of any linked website and bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.
YOU ACCESS ALL LINKS ENTIRELY AT YOUR OWN RISK.
The writer of the above post makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by, or the information contained on these websites.
The writer of the above post accepts no liability for any damage or loss, however caused, in connection with the use of or reliance on any information, material, products, or services contained on or accessed through any such linked websites.

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rural AI Skills Gap Uncovered: Challenges and Solutions

Updated Category News Views 86

Rural Workers Face Distinct AI Challenges Ah, life in the countryside might sound serene, but when it comes to keeping up with AI, rural folks aren't sipping lemonade and waiting on a windfall. The newly unveiled paper from the University of Phoenix College of Doctoral Studies shines a floodlight on some hefty challenges facing rural communities—particularly around...

Continue Reading
Chemours Class Action: Key Deadline Approaches Fast

Updated Category News Views 77

A Rocky Ride for Chemours Investors The ticker might read NYSE:CC, but right now, that might as well stand for "Caution, Cautious," if you ask me. Investors are on high alert with Chemours facing a class action lawsuit, and the stakes couldn’t be higher. Deadline's looming on December 7, 2026, for those gunning for lead plaintiff status. It's a tense time for anyone who...

Continue Reading
Langford Chosen for Navy Mutual's 2026 Bolles Award

Updated Category News Views 225

Awarding a Military Financial Educator There's something profoundly rewarding when hard work and dedication get their due recognition. That's precisely what's happened for Lacey Langford, who’s just been awarded the Lieutenant Timothy Dix Bolles Excellency in Education Award by the Navy Mutual Aid Association, or simply Navy Mutual. This isn’t just some...

Continue Reading
Millrose Properties Faces Legal Storm: Investors Alerted

Updated Category News Views 187

Millrose Properties: A Storm's Brewing Whoa, step back and take a wide-eyed look at Millrose Properties—there’s a storm brewin’ and it’s a doozy! Right now, they’re up against one mighty class action lawsuit, and investors who’ve been hit for over $100k better circle December 8, 2026, on their calendars if they fancy a shot at lead plaintiff glory. We’re...

Continue Reading
SCANOLOGY's AirGO Pad Revolutionizes On-Site Inspections

Updated Category News Views 157

Mobile 3D Scanning — Finally, Some Real Innovation Gone are the days where engineers had to cart around bulky laptops just to finish a simple inspection. SCANOLOGY has thrown a real game-changer into the mix with their new AirGO Pad. It's essentially a slick tablet that keeps your scanning, inspecting, and reporting all in one place, right beside whatever tangled hunk...

Continue Reading
Fashion and Philanthropy Unite at UBCF Kick-off Party

Updated Category News Views 65

Exclusivity and Dedication Mix at UBCF Event When fashion and philanthropy get together, you better believe it's more than just a pleasant evening. The Frederick Anderson Collection is hosting a swanky cocktail reception, kicking off the United Breast Cancer Foundation's (UBCF) highly-anticipated Think Pink Gala, and it's shaping up to be a unique affair wrapped in...

Continue Reading
Fluence Energy Faces Class Action: Investors Beware

Updated Category News Views 116

Storm Clouds Over Fluence Energy I'll tell you, I ain't surprised when companies face the music for dressing up their books. Fluence Energy, Inc. (NASDAQ: FLNC)—those wallopers are now caught in a legal maelstrom with a securities fraud class action lawsuit hanging over their heads. It's hard to feel sorry for 'em when the writing's on the wall. Allegations and...

Continue Reading
UBCF Strikes Big in Times Square with New Billboards

Updated Category News Views 113

From the Shadows to the Spotlight Ever seen someone step up to the plate and knock it out of the park? That's what the United Breast Cancer Foundation (UBCF) is doing by plastering their mission right across Times Square. Talk about grabbing the bull by the horns, eh? With not one, but two billboards now gracing one of the globe's most iconic public spaces, they've...

Continue Reading
HanAll F&B Pioneers New Path for Domestic Rice Noodles

Updated Category News Views 173

New Spin on an Old Favorite: Rice Noodles Forget about the same old wheat noodles clogging up the pantry. HanAll F&B is revamping the noodle game with a homegrown twist, setting sights on a future where Korean rice isn't just for steaming, soup, or sushi. This outfit from Taebaek, Gangwon, has got its hands deep in the rice flour, finessing a patent that aims to make...

Continue Reading
Zhimeng Biopharma Hits Key Milestone in ALS Drug Trial

Updated Category News Views 156

Pivotal Point for Zhimeng's ALS Efforts Folks, get this—Zhimeng Biopharma's rolling out the big guns here with a significant step forward in their ALS treatment quest. This company just wrapped up patient enrollment for their next-gen ALS drug, CB03-154. We're talking about 255 patients now on board for a Phase 2/3 trial. The ground's shaking a bit because this...

Continue Reading

Top 5 Most Recently Viewed Articles

EarthCam Unveils Revolutionary AI Camera for Construction Safety

Updated Category News Views 302

EarthCam Launches AI-Powered Mobile StreamCam Robotic EarthCam, a leader in visual technology, has unveiled its new Mobile StreamCam Robotic aimed at enhancing monitoring capabilities in interior construction. This innovative camera is designed to combine advanced live-streaming features with smart AI insights, providing construction teams with real-time data and...

Continue Reading
Investors Should Act Now: iLearningEngines Class Action News

Updated Category News Views 140

Understanding the iLearningEngines Class Action Lawsuit The well-regarded law firm Faruqi & Faruqi, LLP is currently inviting investors of iLearningEngines, Inc. to stay informed about an important class action lawsuit. This lawsuit revolves around allegations that iLearningEngines engaged in misleading practices fundamentally impacting its investors. The deadline to seek...

Continue Reading
Sarepta's Gene Therapy Under Investigation Following Tragic Death

Updated Category News Views 130

Investigation into Elevidys Following a Tragic Incident The U.S. Food and Drug Administration (FDA) has begun an investigation into the unfortunate death of a young boy who was administered Elevidys, Sarepta Therapeutics Inc.’s gene therapy designed for treating Duchenne muscular dystrophy. This announcement came after market close, raising concerns regarding the safety...

Continue Reading
2Rivers Group Enhances Market Position in West Africa

Updated Category News Views 56

2Rivers Group Expands Operations into West Africa 2Rivers Group is excited to announce its ongoing expansion into the West African market, reinforcing its status as a key entity in the global energy trading and distribution landscape. This initiative aligns perfectly with the company’s vision of achieving sustainable growth in important markets around the world....

Continue Reading
Pathward Financial Announces Upcoming Q1 2025 Earnings Call

Updated Category News Views 189

Pathward Financial to Announce Earnings for First Quarter 2025 Pathward Financial, Inc. has made an important announcement regarding its upcoming financial results for the first quarter of fiscal year 2025. The release is set for Tuesday, after the market closes, and the company is eager to share insights from these results. Conference Call Scheduled A conference call and...

Continue Reading